The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBaronsmead Vt Regulatory News (BVT)

Share Price Information for Baronsmead Vt (BVT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 53.00
Bid: 51.50
Ask: 54.50
Change: 0.00 (0.00%)
Spread: 3.00 (5.825%)
Open: 53.00
High: 53.00
Low: 53.00
Prev. Close: 53.00
BVT Live PriceLast checked at -
Baronsmead Venture Trust is an Investment Trust

To achieve long-term investment returns for private investors by investing primarily in a diverse portfolio of UK growth businesses, whether unquoted or traded on AIM.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Allotment of Shares and Total Voting Rights

15 Feb 2024 14:00

RNS Number : 3209D
Baronsmead Venture Trust PLC
15 February 2024

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, THE UNITED STATES OR ANY MEMBER STATE OF THE EEA (OTHER THAN ANY MEMBER STATE OF THE EEA WHERE THE COMPANY'S SECURITIES MAY BE LEGALLY MARKETED), OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT. THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER TO ISSUE OR SELL, OR ANY SOLICITATION OF ANY OFFER TO SUBSCRIBE OR PURCHASE, ANY INVESTMENTS IN ANY JURISDICTION.

Baronsmead Venture Trust plc

LEI: 213800VQ1PQHOJXDDQ88

15 February 2024

Allotment of Shares and Total Voting Rights

The Board of Baronsmead Venture Trust plc (the "Company") announced on 24 November 2023 that the Company, together with Baronsmead Second Venture Trust plc, had published a prospectus (the "Prospectus") in relation to offers for subscription to raise up to £30 million in aggregate with the discretion to utilise over-allotment facilities to raise up to a further £20 million in aggregate (the "Offers" and each an "Offer").

On 15 February 2024 and in accordance with the Allotment Formula set out in the Prospectus, the Company allotted 7,702,241 Ordinary Shares of 10 pence each (the "New Ordinary Shares") in the capital of the Company pursuant to the second allotment under the Offer conditional only on Admission (the timetable for which is set out in more detail below). The New Ordinary Shares were issued at prices of between 56.92 pence per New Ordinary Share and 59.68 pence per New Ordinary Share, depending on the amount of Offer Costs, any Initial Commission waived, any Initial Adviser Charges, any Early Bird Discount associated with an Application and based on the net asset value per Ordinary Share as at 31 January 2024 (being the last published net asset value per Ordinary Share as announced on 7 February 2024, adjusted for dividends following the ex-dividend date).

Application will shortly be made for the New Ordinary Shares to be admitted to the premium segment of the Official List of the Financial Conduct Authority and to trading on the premium segment of London Stock Exchange plc's main market for listed securities ("Admission"). It is expected that Admission will occur and dealing will commence in the New Ordinary Shares on or around 22 February 2024. When issued, the New Ordinary Shares will rank pari passu with the existing Ordinary Shares.

As a result of the issue, the total number of Ordinary Shares in issue will be 372,225,504 (excluding the 33,187,409 Ordinary Shares currently held in Treasury) with each Ordinary Share carrying one vote each. Therefore, the total voting rights in the Company will be 372,225,504. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure Guidance and Transparency Rules.

The New Ordinary Shares will be issued in registered form and may be held in uncertificated form. Definitive documents of title are expected to be dispatched within 10 business days of allotment. The New Ordinary Shares will be eligible for settlement through CREST with effect from Admission.

Unless the context requires otherwise, terms defined in the Prospectus have the same meaning where used in this announcement.

For further information please contact:

Baronsmead VCT Investor Relations

020 7382 0999

baronsmeadvcts@greshamhouse.com

Important Information

This Announcement is an advertisement for the purposes of the Prospectus Regulation Rules of the UK Financial Conduct Authority ("FCA") and is not a prospectus. This Announcement does not constitute or form part of, and should not be construed as, an offer for sale or subscription of, or solicitation of any offer to subscribe for or to acquire, any ordinary shares in Baronsmead Venture Trust plc or Baronsmead Second Venture Trust plc (together the "Companies") in any jurisdiction, including in or into Australia, Canada, Japan, the Republic of South Africa, the United States or any member state of the EEA (other than any member state of the EEA where the Companies' securities may be lawfully marketed). Investors should not subscribe for or purchase any ordinary shares referred to in this Announcement except on the basis of information in the prospectus (the "Prospectus") in its final form, published on 24 November 2023 by Baronsmead Venture Trust plc and Baronsmead Second Venture Trust plc, together with the supplementary prospectus published on 19 January 2024 (the "Supplementary Prospectus"), in connection with the Offer. A copy of the Prospectus and Supplementary Prospectus is available for inspection, subject to certain access restrictions, from the Company's registered office, for viewing at the National Storage Mechanism at https://data.fca.org.uk/#/nsm/nationalstoragemechanism and on the Company's website (http://www.baronsmeadvcts.co.uk). Approval of the Prospectus and Supplementary Prospectus by the FCA should not be understood as an endorsement of the securities that are the subject of the Prospectus and Supplementary Prospectus. Potential investors are recommended to read the Prospectus and Supplementary Prospectus before making an investment decision in order to fully understand the potential risks and rewards associated with a decision to invest in the Companies' securities.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
IOEUVSORSNUUAAR
Date   Source Headline
27th Sep 20194:27 pmRNSTransaction in Own Shares
23rd Sep 201912:00 pmRNSDividend Policy Change Announcement
5th Sep 201910:15 amRNSNet Asset Value(s)
8th Aug 20194:00 pmRNSDividend Declaration
8th Aug 20194:00 pmRNSIntention to Fundraise
6th Aug 20193:00 pmRNSNet Asset Value(s)
1st Aug 20195:31 pmRNSTotal Voting Rights
30th Jul 20195:23 pmRNSTransaction in Own Shares
10th Jul 20195:45 pmRNSNet Asset Value(s)
1st Jul 201911:40 amRNSTotal Voting Rights
27th Jun 20195:22 pmRNSDirector/PDMR Shareholding
27th Jun 20195:04 pmRNSTransaction in Own Shares
6th Jun 20195:20 pmRNSNet Asset Value(s)
3rd Jun 20197:00 amRNSTotal Voting Rights
29th May 20195:36 pmRNSTransaction in Own Shares
23rd May 20199:00 amRNSHalf-year Report
7th May 201910:30 amRNSNet Asset Value(s)
12th Apr 20194:00 pmRNSNet Asset Value(s)
2nd Apr 20195:39 pmRNSDirector/PDMR Shareholding
1st Apr 20192:42 pmRNSTotal Voting Rights
28th Mar 20194:56 pmRNSTransaction in Own Shares
12th Mar 20193:02 pmRNSDirector/PDMR Shareholding
8th Mar 201910:30 amRNSReplacement Transaction in Own Shares
7th Mar 20195:22 pmRNSTransaction in Own Shares
5th Mar 20194:00 pmRNSNet Asset Value(s)
1st Mar 201912:10 pmRNSTotal Voting Rights
27th Feb 20194:44 pmRNSResult of AGM
12th Feb 201912:43 pmRNSDirector/PDMR Shareholding - Replacement
8th Feb 20194:13 pmRNSDirector/PDMR Shareholding
7th Feb 20191:00 pmRNSIssue of New Shares
5th Feb 201910:45 amRNSNet Asset Value(s)
24th Jan 201911:30 amRNSNet Asset Value(s)
18th Jan 20192:57 pmRNSOffer for Subscription - Update
9th Jan 20199:00 amRNSPublication of a Prospectus
2nd Jan 201911:47 amRNSTotal Voting Rights
21st Dec 20185:24 pmRNSTransaction in Own Shares
6th Dec 20183:30 pmRNSNet Asset Value(s)
3rd Dec 20183:40 pmRNSTotal Voting Rights
3rd Dec 20187:00 amRNSChange of Registered Office
27th Nov 20185:59 pmRNSTransaction in Own Shares
23rd Nov 201811:29 amRNSAnnual Financial Report - Replacement
23rd Nov 20187:00 amRNSAnnual Financial Report
8th Nov 20185:06 pmRNSChange in management arrangements
6th Nov 20186:05 pmRNSNet Asset Value(s)
15th Oct 201812:15 pmRNSNet Asset Value(s)
1st Oct 201812:16 pmRNSTotal Voting Rights
27th Sep 20185:31 pmRNSTransaction in Own Shares
6th Sep 20184:00 pmRNSNet Asset Value(s)
9th Aug 20184:15 pmRNSDividend Declaration
9th Aug 20184:15 pmRNSIntention to Fundraise

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.